Hospital & Healthcare Services · Founded 1994 · www.ngind.com · BSE 530897 · · ISIN INE825C01018
No Notes Added Yet
Business
NG Industries Ltd., operating in the Hospital & Healthcare Services sector, is primarily involved in providing medical and healthcare services. Its core business model typically involves operating a network of hospitals and healthcare facilities that offer a range of services from basic consultations and diagnostics to complex surgeries and specialized treatments. The company generates revenue through fees charged for medical procedures, consultations, room occupancy (inpatient care), diagnostic tests, pharmacy sales, and other related services. Revenue sources often include direct patient payments, payments from health insurance providers, and corporate tie-ups.
Revenue Mix
While specific revenue mix for NG Industries Ltd. is not publicly available, a typical hospital and healthcare services provider in India derives revenue from several key segments. These commonly include:
Inpatient Services: Revenue from patients admitted for treatment, surgeries, or long-term care, including bed charges, surgeon fees, and consumables.
Outpatient Services: Revenue from consultations, minor procedures, and daycare services.
Diagnostics: Income from various pathology and radiology tests.
Pharmacy: Revenue from in-house pharmacies catering to patients.
Specialized Services: Contributions from high-value specialties such as cardiology, oncology, orthopedics, neurology, etc.
Other Services: Such as health check-ups, emergency services, and rehabilitation.
Industry
The Indian Hospital & Healthcare Services industry is characterized by a mix of corporate hospital chains, standalone multi-specialty and single-specialty hospitals, government facilities, and smaller clinics. It is a growing, yet highly competitive and fragmented sector. Without specific data on NG Industries Ltd.'s scale (e.g., number of beds, geographic footprint, revenue), its exact positioning relative to peers is difficult to ascertain. It likely competes with established large corporate hospital groups, regional hospital chains, and local standalone hospitals. Positioning often depends on factors like brand reputation, geographic presence, specialization in certain medical fields, and price points.
MOAT
For a healthcare services company, potential competitive advantages (moats) can include:
Brand Reputation & Trust: A long-standing reputation for quality care, ethical practices, and successful patient outcomes builds trust, which is critical in healthcare.
Skilled Talent Pool: Ability to attract and retain highly reputed doctors, surgeons, and medical staff creates a significant competitive edge.
Specialized Infrastructure: Investments in advanced medical technology, specialized equipment, and state-of-the-art facilities can differentiate a provider.
Geographic Density/Network Effect: A strong presence in a particular region or city can create local market dominance and patient preference.
Scale Economies: Larger chains can achieve better purchasing power for medical supplies and pharmaceuticals, and optimize back-office operations.
NG Industries Ltd. would need to possess some combination of these to establish a durable competitive advantage.
Growth Drivers
Key factors that can drive growth for NG Industries Ltd. over the next 3-5 years include:
Demographic Trends: India's large and aging population, coupled with increasing prevalence of chronic diseases, fuels demand for healthcare services.
Rising Income & Health Awareness: Growing disposable incomes and greater health consciousness lead to increased willingness to spend on quality healthcare.
Health Insurance Penetration: Expanding coverage of health insurance schemes (both private and government-backed like Ayushman Bharat) makes healthcare more accessible.
Medical Tourism: India's growing reputation as a destination for affordable and quality medical treatment attracts international patients.
Expansion & Specialization: Organic growth through increasing bed capacity, adding new facilities, or expanding into niche specialty areas.
Technological Adoption: Integration of new medical technologies, digital health solutions, and telemedicine can enhance service delivery and reach.
Risks
NG Industries Ltd. faces several business risks:
Intense Competition: The fragmented nature of the Indian healthcare market means strong competition from both established players and new entrants, potentially leading to pricing pressures.
Regulatory & Pricing Controls: Government interventions such as caps on pricing for medical procedures, drugs, or medical devices can impact profitability. Changes in licensing or quality standards also pose risks.
Shortage of Skilled Professionals: Attracting and retaining qualified doctors, nurses, and other medical staff is a persistent challenge, impacting operational quality and costs.
High Capital Expenditure: Establishing and upgrading healthcare facilities requires substantial capital investment, leading to potential financial strain if not managed efficiently.
Medical Malpractice & Litigation: Risks associated with medical errors, patient safety, and potential lawsuits can damage reputation and incur significant legal costs.
Technology Obsolescence: Rapid advancements in medical technology necessitate continuous investment to remain competitive.
Management & Ownership
In India, many companies, especially those with a long history, are promoter-driven. The vision, integrity, and strategic direction provided by the promoter group are often crucial to the company's success. Management quality depends on the experience, execution track record, and corporate governance standards upheld by the leadership team. Without specific information, it's difficult to comment on the management quality of NG Industries Ltd. Ownership structure typically involves a significant promoter holding, alongside institutional investors and public shareholders, though the exact proportions are not specified here.
Outlook
NG Industries Ltd. operates in a sector with significant long-term growth tailwinds driven by India's demographics, increasing incomes, and evolving healthcare needs. The potential for expansion, both geographically and in terms of specialty services, presents opportunities for growth. However, this potential is balanced by several challenges. The industry faces intense competition, continuous regulatory scrutiny, and the need for substantial capital investment to maintain and expand facilities. Attracting and retaining top medical talent remains a critical factor for sustained success. The company's ability to navigate regulatory changes, manage operational costs effectively, differentiate its services, and execute its growth strategies will be key determinants of its future performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Other Income | 2 | 0 | 3 | 8 | -3 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 6 | 4 | 8 | 12 | 1 | 4 | 4 | 5 | 5 | 4 |
| Total Expenditure | 4 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 4 | 4 |
| Operating Profit | 2 | 1 | 4 | 8 | -3 | 0 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 1 | 3 | 8 | -3 | 0 | 1 | 1 | 1 | 1 |
| Provision for Tax | 0 | 0 | 1 | 1 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 2 | 0 | 3 | 7 | -2 | 0 | 0 | 0 | 1 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 2 | 0 | 3 | 7 | -2 | 0 | 0 | 0 | 1 | 0 |
| Adjusted Earnings Per Share | 5.8 | 1.5 | 8.8 | 20 | -7.3 | 0.6 | 1.3 | 1.3 | 2.1 | 1.2 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 15 | 17 | 17 | 17 | 18 | 19 | 12 | 18 | 19 | 17 | 17 | 16 |
| Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 5 | 8 | 0 |
| Total Income | 15 | 17 | 17 | 17 | 18 | 19 | 12 | 20 | 27 | 21 | 25 | 18 |
| Total Expenditure | 12 | 14 | 15 | 15 | 15 | 16 | 11 | 16 | 17 | 15 | 15 | 16 |
| Operating Profit | 3 | 3 | 3 | 2 | 2 | 3 | 1 | 4 | 10 | 7 | 10 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 10 | 6 | 9 | 4 |
| Provision for Tax | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Profit After Tax | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 5 | 8 | 1 |
| Adjustments | 0 | 0 | 0 | 0 | -1 | -2 | 5 | 6 | -3 | 4 | -4 | 0 |
| Profit After Adjustments | 1 | 2 | 1 | 1 | 1 | -0 | 6 | 9 | 5 | 9 | 4 | 1 |
| Adjusted Earnings Per Share | 4.3 | 4.6 | 4.2 | 2.8 | 3.4 | 4.4 | 1.8 | 7.8 | 24.8 | 15 | 23.1 | 5.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | -2% | -2% | 1% |
| Operating Profit CAGR | 43% | 36% | 27% | 13% |
| PAT CAGR | 60% | 39% | 52% | 23% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -30% | -8% | 11% | 3% |
| ROE Average | 21% | 23% | 17% | 14% |
| ROCE Average | 24% | 26% | 20% | 17% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 14 | 14 | 14 | 12 | 11 | 9 | 15 | 24 | 28 | 36 | 39 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -0 | -0 | -0 | -2 | -2 | -2 | -1 | 2 | 1 | 2 | 1 |
| Total Current Liabilities | 3 | 3 | 3 | 2 | 2 | 5 | 2 | 2 | 2 | 2 | 2 |
| Total Liabilities | 17 | 17 | 18 | 12 | 11 | 12 | 16 | 27 | 31 | 40 | 42 |
| Fixed Assets | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 6 | 6 |
| Other Non-Current Assets | 10 | 10 | 10 | 5 | 4 | 4 | 8 | 16 | 23 | 29 | 32 |
| Total Current Assets | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 5 | 3 | 5 | 4 |
| Total Assets | 17 | 17 | 18 | 12 | 11 | 12 | 16 | 27 | 31 | 40 | 42 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 2 |
| Cash Flow from Operating Activities | 2 | 2 | 2 | 2 | 4 | 3 | 1 | -2 | 3 | -1 | 2 |
| Cash Flow from Investing Activities | -1 | -1 | -1 | -1 | -1 | -3 | 2 | 1 | -2 | 2 | -1 |
| Cash Flow from Financing Activities | -2 | -1 | -1 | -2 | -2 | 0 | -3 | 0 | -1 | -1 | -1 |
| Net Cash Inflow / Outflow | -1 | -0 | 0 | -1 | 1 | -0 | 1 | -0 | 0 | 1 | -0 |
| Closing Cash & Cash Equivalent | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 2 | 2 | 2 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.27 | 4.57 | 4.24 | 2.82 | 3.36 | 4.38 | 1.83 | 7.79 | 24.82 | 15.02 | 23.1 |
| CEPS(Rs) | 7.82 | 6.3 | 5.94 | 4.6 | 5.06 | 6.03 | 3.3 | 9.51 | 26.39 | 16.8 | 24.93 |
| DPS(Rs) | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 0 | 0 | 3.5 | 3.5 | 3.5 | 3.5 |
| Book NAV/Share(Rs) | 42.81 | 43.15 | 43.18 | 35.36 | 32.75 | 27.87 | 44.79 | 71.37 | 84.17 | 107.85 | 114.96 |
| Core EBITDA Margin(%) | 18.2 | 16.62 | 15.53 | 12.78 | 13.25 | 13.73 | 10.26 | 12.84 | 10.08 | 11.96 | 11.23 |
| EBIT Margin(%) | 13.74 | 14.61 | 13.27 | 10.1 | 10.81 | 11.83 | 7.64 | 18.52 | 52.05 | 35.12 | 55.88 |
| Pre Tax Margin(%) | 13.17 | 14.27 | 12.85 | 9.65 | 9.79 | 10.96 | 7.01 | 18.02 | 51.59 | 34.68 | 55.25 |
| PAT Margin (%) | 9.61 | 9.04 | 8.21 | 5.44 | 6.37 | 7.93 | 5.17 | 14.16 | 44.46 | 29.82 | 46.77 |
| Cash Profit Margin (%) | 17.64 | 12.48 | 11.52 | 8.88 | 9.6 | 10.93 | 9.3 | 17.3 | 47.27 | 33.34 | 50.48 |
| ROA(%) | 8.32 | 9.1 | 8.17 | 6.35 | 9.59 | 12.71 | 4.38 | 11.96 | 28.74 | 14.25 | 18.98 |
| ROE(%) | 9.97 | 10.63 | 9.81 | 7.18 | 9.86 | 14.44 | 5.04 | 13.41 | 31.91 | 15.65 | 20.73 |
| ROCE(%) | 12.93 | 15.93 | 14.33 | 11.81 | 14.94 | 17.8 | 6.57 | 17.19 | 36.58 | 17.94 | 23.83 |
| Receivable days | 3.07 | 5.23 | 7.59 | 9.31 | 10.19 | 9.84 | 12.32 | 10.95 | 8.27 | 2.33 | 6.31 |
| Inventory Days | 15.49 | 14.68 | 16.87 | 16.73 | 14.95 | 12.24 | 17.22 | 33.48 | 33.72 | 13.89 | 15.24 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 19.68 | 16.38 | 18.58 | 27.3 | 19.11 | 10.28 | 21.72 | 7.96 | 3.22 | 10.41 | 7.06 |
| Price/Book(x) | 1.96 | 1.73 | 1.82 | 2.18 | 1.96 | 1.61 | 0.89 | 0.87 | 0.95 | 1.45 | 1.42 |
| Dividend Yield(%) | 4.17 | 4.68 | 4.45 | 4.55 | 5.46 | 0 | 0 | 5.65 | 4.38 | 2.24 | 2.15 |
| EV/Net Sales(x) | 1.88 | 1.49 | 1.56 | 1.55 | 1.21 | 0.92 | 1.01 | 1.08 | 1.37 | 3.03 | 3.27 |
| EV/Core EBITDA(x) | 8.64 | 8.26 | 9.41 | 11.43 | 8.61 | 6.2 | 8.53 | 4.98 | 2.5 | 7.85 | 5.48 |
| Net Sales Growth(%) | 7.73 | 13.89 | 2.07 | 0.48 | 1.75 | 4.73 | -35.77 | 55.01 | 1.54 | -9.74 | -1.99 |
| EBIT Growth(%) | -14.18 | 21.11 | -7.28 | -23.5 | 8.85 | 14.59 | -58.49 | 275.62 | 185.34 | -39.1 | 55.96 |
| PAT Growth(%) | -5.9 | 7.14 | -7.31 | -33.47 | 19.12 | 30.35 | -58.14 | 325.04 | 218.74 | -39.47 | 53.75 |
| EPS Growth(%) | -5.9 | 7.14 | -7.31 | -33.47 | 19.12 | 30.35 | -58.14 | 325.03 | 218.74 | -39.47 | 53.75 |
| Debt/Equity(x) | 0.07 | 0.08 | 0.13 | 0.13 | 0.11 | 0.32 | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 |
| Current Ratio(x) | 0.8 | 0.78 | 0.77 | 1 | 1.2 | 0.5 | 1.29 | 3.11 | 1.6 | 2.88 | 1.65 |
| Quick Ratio(x) | 0.57 | 0.5 | 0.53 | 0.57 | 1.38 | 0.51 | 3.01 | 2.8 | 2.6 | 2.77 | 1.56 |
| Interest Cover(x) | 24.06 | 43.15 | 31.76 | 22.45 | 10.62 | 13.58 | 12.01 | 36.66 | 113.07 | 79.36 | 88.23 |
| Total Debt/Mcap(x) | 0.04 | 0.05 | 0.07 | 0.06 | 0.06 | 0.2 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | -2% | -2% | +1% |
| Operating Profit CAGR | +43% | +36% | +27% | +13% |
| PAT CAGR | +60% | +39% | +52% | +23% |
| Share Price CAGR | -30% | -8% | +11% | +3% |
| ROE Average | +21% | +23% | +17% | +14% |
| ROCE Average | +24% | +26% | +20% | +17% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 | 74.5 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 | 25.5 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.